Eva Hernando

List of Publications by Citations

Source: https://exaly.com/author-pdf/7670996/eva-hernando-publications-by-citations.pdf
Version: 2024-04-20

54 papers	3,251 citations	23 h-index	57 g-index
60 ext. papers	3,859 ext. citations	10.4 avg, IF	4.62 L-index

#	Paper	IF	Citations
54	Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. *Cancer Cell*, **2007**, 11, 9-23	24.3	488
53	Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 1814-9	11.5	461
52	The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. *Nature*, **2010**, 468, 1105-9	50.4	291
51	miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. *Cancer Cell*, **2011**, 20, 104-18	24.3	278
50	Melanoma MicroRNA signature predicts post-recurrence survival. *Clinical Cancer Research*, **2010**, 16, 1577-86	12.9	180
49	BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. *Cancer Research*, **2013**, 73, 6264-76	10.1	161
48	A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis. *Cancer Cell*, **2017**, 31, 804-819.e7	24.3	146
47	Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. *Cell Reports*, **2014**, 9, 234-247	10.6	144
46	Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma. *Molecular Cell*, **2015**, 59, 75-88	17.6	128
45	Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. *Cancer Cell*, **2020**, 37, 55-70.e15	24.3	113
44	FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. *Nature Cell Biology*, **2015**, 17, 322-332	23.4	89
43	miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. *Cancer Research*, **2018**, 78, 1017-1030	10.1	88
42	MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. *Carcinogenesis*, **2012**, 33, 1823-32	4.6	73
41	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. *Cancer Discovery*, **2020**, 10, 1352-1373	24.4	62
40	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. *Molecular Cell*, **2017**, 68, 731-744.e9	17.6	53
39	A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. *Clinical Cancer Research*, **2015**, 21, 4903-12	12.9	49
38	Anti-miR182 reduces ovarian cancer burden, invasion, and metastasis: an in vivo study in orthotopic xenografts of nude mice. *Molecular Cancer Therapeutics*, **2014**, 13, 1729-39	6.1	47

37	Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. *Cancer Research*, **2011**, 71, 2561-71	10.1	45
36	Revisiting determinants of prognosis in cutaneous melanoma. *Cancer*, **2015**, 121, 4108-23	6.4	40
35	Identification of metastasis-suppressive microRNAs in primary melanoma. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	38
34	BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma. *Cancer Medicine*, **2016**, 5, 1183-93	4.8	38
33	circSamd4 represses myogenic transcriptional activity of PUR proteins. *Nucleic Acids Research*, **2020**, 48, 3789-3805	20.1	34
32	Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability. *Cell Death and Differentiation*, **2018**, 25, 935-950	12.7	29
31	MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. *Pigment Cell and Melanoma Research*, **2017**, 30, 328-338	4.5	23
30	A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis. *Molecular Cancer Research*, **2019**, 17, 109-119	6.6	20
29	Limited miR-17-92 overexpression drives hematologic malignancies. *Leukemia Research*, **2015**, 39, 335-41	2.7	17
28	Cancer. Aneuploidy advantages?. *Science*, **2008**, 322, 692-3	33.3	14
27	A TGF□miR-182-BRCA1 axis controls the mammary differentiation hierarchy. *Science Signaling*, **2016**, 9, ra118	8.8	12
26	Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics. *Melanoma Research*, **2018**, 28, 380-389	3.3	12
25	The State of Melanoma: Emergent Challenges and Opportunities. *Clinical Cancer Research*, **2021**, 27, 2678-2697	12.9	11
24	Mutation burden as a potential prognostic marker of melanoma progression and survival.. *Journal of Clinical Oncology*, **2017**, 35, 9567-9567	2.2	10
23	TYRP1 mRNA goes fishing for miRNAs in melanoma. *Nature Cell Biology*, **2017**, 19, 1311-1312	23.4	8
22	Kr□ppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions. *Oncotarget*, **2017**, 8, 26298-26311	3.3	8
21	Functional analysis of RPS27 mutations and expression in melanoma. *Pigment Cell and Melanoma Research*, **2020**, 33, 466-479	4.5	8
20	In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis. *Frontiers in Oncology*, **2013**, 3, 127	5.3	6

19	HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness. *ELife*, **2021**, 10,	8.9	6
18	Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis. *Nature Communications*, **2021**, 12, 1214	17.4	6
17	Expression of miR-16 is not a suitable reference for analysis of serum microRNAs in melanoma patients. *Journal of Biomedical Science and Engineering*, **2012**, 05, 647-651	0.7	4
16	Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients. *Journal of Translational Medicine*, **2021**, 19, 47	8.5	4
15	Regulates the Proliferation Capacity of Bone-Marrow Derived Mesenchymal Stem Cells. *Cells*, **2020**, 9,	7.9	3
14	Melanoma-secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis.. *Cancer Discovery*, **2022**,	24.4	2
13	Characterization of MicroRNAs Regulating FOXO Expression. *Methods in Molecular Biology*, **2019**, 1890, 13-28	1.4	1
12	The histone demethylase PHF8 regulates TGFβsignaling and promotes melanoma metastasis.. *Science Advances*, **2022**, 8, eabi7127	14.3	1
11	miRNA Decoy Screen Reveals miR-124a as a Suppressor of Melanoma Metastasis.. *Frontiers in Oncology*, **2022**, 12, 852952	5.3	0
10	Human genes differ by their UV sensitivity estimated through analysis of UV-induced silent mutations in melanoma. *Human Mutation*, **2020**, 41, 1751-1760	4.7	
9	Preclinical testing supports combined BET and BRAF inhibition as a promising therapeutic strategy for melanoma.. *Journal of Clinical Oncology*, **2014**, 32, 9072-9072	2.2	
8	Targeted next-generation sequencing of melanoma patient samples to reveal mutations in non-protein coding regions of targetable oncogenes.. *Journal of Clinical Oncology*, **2016**, 34, 9559-9559	2.2	
7	Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target.. *Journal of Clinical Oncology*, **2016**, 34, 9524-9524	2.2	
6	Newmouse models of melanoma metastasis and differences in brain tropism and metastatic growth pattern.. *Journal of Clinical Oncology*, **2012**, 30, e19015-e19015	2.2	
5	MicroRNA alterations associated with BRAF status in melanoma.. *Journal of Clinical Oncology*, **2012**, 30, 8565-8565	2.2	
4	Early alterations of microRNA expression to predict and modulate melanoma metastasis.. *Journal of Clinical Oncology*, **2012**, 30, 8550-8550	2.2	
3	Identification of melanoma-specific alterations in cell surface glycosylation.. *Journal of Clinical Oncology*, **2012**, 30, e19018-e19018	2.2	
2	Melanoma recurrence risk stratification using Bayesian systems biology modeling.. *Journal of Clinical Oncology*, **2013**, 31, 9089-9089	2.2	

1 Targeting BET proteins in melanoma: A novel treatment approach.. *Journal of Clinical Oncology*, **2013**, 31, 9091-9091 2.2